Term drift
A pharmaceutical dossier that calls the same excipient by one Portuguese term on page 4 and a synonym on page 40 reads, to a regulator, as two different substances. The same happens with financial instruments in a CVM filing, or with an ingredient classification in a MAPA submission. The fix is not a better translator — it's a locked glossary, agreed before translation starts, that every linguist on the job is required to use, and that is checked mechanically at the end, not proofread by eye.
Untranslated attachments
The main report gets careful attention; the appendix, the lab certificate, the supplier declaration, or the annex referenced on page 12 gets left in English because it arrived late or was assumed to be “supporting material.” Brazilian regulators do not treat attachments as optional. A filing with a translated body and an untranslated annex is, procedurally, an incomplete filing — and it is returned as one.
Version drift
The most avoidable failure. Legal and regulatory teams revise source documents until the last hour before filing. If the translation team is working from version 3 while legal has moved to version 4, the submission goes out with a translated document that no longer matches its own English source. The only real defense is a single point of control: one linguist team, working from one shared, versioned source, with translation as the last step before submission rather than a parallel track.
Key takeaways
- Regulators reject filings for consistency problems, not writing-quality problems.
- A locked glossary, agreed before translation starts, prevents term drift across a long dossier.
- Attachments and annexes need the same translation discipline as the main document.
Filing with ANVISA, CVM, or MAPA on a deadline?
Build the terminology list and the attachment inventory before translation starts, not after a rejection.